SPRY logo

SPRY ARS Pharmaceuticals, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$2.96
-0.40 (-11.90%)

ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasa…

Market Cap: $297.56Mars-pharma.com

Price

$5.65-68.06%
$5.13$9.54$13.94$18.35
Jul 2025Aug 2026

Social Signal Score

61
5d
70
1 mentions
+0.0%
30d
65
4 mentions
+0.0%
60d
62
5 mentions
+0.0%
90d
45
8 mentions
+0.0%
news: 8

Analyst Ratings

10 analysts
Holdconsensus
Strong Buy 0Buy 4Hold 6Sell 0Strong Sell 0
Avg price target$15+406.8%
Low $15Median $15High $15
Current Consensus

52-week range

$5.13$14.87
Last close
$5.65
Off 52w high
-62.0%
200-day average
$8.78
vs 200-day
-35.6%

Compare with other stocks off their highs

Revenue

$37.71M
$0.00$28.86M$57.72M$86.58M
Dec 2019Sep 2026

Analyst Estimates

FY2025
$-1.72
$-1.84–$-1.53
5 analysts
FY2026
$-1.81
$-1.89–$-1.74
3 analysts
FY2027
$-0.74
$-0.87–$-0.64
3 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Donn Casale
Sector
Healthcare
Industry
Biotechnology
Employees
203
Beta
0.88
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
-3.19
ars-pharma.com